NEW YORK (GenomeWeb News) – Horizon Discovery announced on its website today that it has inked a collaborative agreement with Janssen Pharmaceutica division Ortho Biotech Oncology Research & Development.

Cambridge, UK-based Horizon said that the deal covers the licensing of certain of its X-MAN cell lines including major cancer-causing genes and their matched normal genetic backgrounds. Horizon said that the cell lines could help the J&J unit to gather information related to selectivity and mode of action of drug candidates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.